Alterity Therapeutics Limited’s August 28, 2026 report includes a securities Quotation application identified as 99.1 and signed by Chairman Julian Babarczy. Investors gain a precise reference to the securities-related application and its authorised signatory, alongside the company’s Melbourne principal executive office.

Key Highlights

  • Alterity Therapeutics Limited identifies itself as a development stage enterprise.
  • Registration statement references include 333-251073, 333-248980, 333-228671, 333-274816, 333-251647, 333-231417 and 333-250076.
  • Alterity Therapeutics Limited’s August 2026 report identifies a securities quotation application designated 99.1.
  • The materials describe Alterity Therapeutics Limited as a development stage enterprise.

Report Period and Company Name

The materials concern Alterity Therapeutics Limited’s report covering August 2026. They identify the company by its full legal name, Alterity Therapeutics Limited, rather than using only an abbreviated reference.

The report’s period and company identification establish the basic setting for the securities and corporate information described in the article.

Securities Quotation Application

The report carries a securities quotation application designated 99.1. This designation identifies the securities-related document associated with the report and is the specific application reference emphasized in the materials.

The article characterizes the 99.1 application as the report’s identified securities-related submission. That description connects the application designation directly with the securities documentation included in the report.

Development Stage Enterprise

The materials describe Alterity Therapeutics Limited as a development stage enterprise. This wording is presented as part of the company description accompanying the August report and its securities-related information.

The development stage characterization is the only enterprise description supplied in the article. It should therefore be read as the stated description of the company in these materials, without adding another Business classification.

Registration Statement References

The materials list registration statement references numbered 333-251073, 333-248980, 333-228671, 333-274816, 333-251647, 333-231417 and 333-250076. These references appear among the report’s securities and filing details.

The listed numbers are reproduced as registration statement references in the article.

Securities and Exchange Act Details

The document identifies the Securities and Exchange Commission in Washington, D.C. 20549. It also cites the Securities Exchange Act of 1934, placing the report’s stated securities information alongside those named regulatory details.

Both the commission identification and the statutory citation are expressly included in the materials.1.

Signature and Date

Julian Babarczy signed Alterity Therapeutics Limited’s report and is identified as chairman. The signature date is August 28, 2026, which is the date expressly attached to the signed report in the materials.

The signing information completes the report’s principal identifying details described in the article. Together with the August 2026 coverage, the full legal name, application designation, registration references and regulatory citations, it records who signed the report and when.

Source(s)

  • https://www.sec.gov/Archives/edgar/data/1131343/000143774926029129/athe20260828d_6k.htm